The strategic merger integrates Crown Bioscience’s leading translational technology platform providing drug target validation, efficacy testing and patient response characterization with JSR’s in v...
As a premier contract research organization (CRO), CrownBio has deep industry relationships and a global footprint that will complement JSR’s already global presence.
Recently published work in the Journal of Endocrinological Investigation and Nature’s Scientific Reports demonstrates the advantages of a new method using DSI’s HD-XG implantable glucose device and...
These joint publications illustrate the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical Candidates Designed to Target Cancers of High Unmet Need
Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic
Paper in Biotechnology and Bioengineering describes faster and more efficient technology for isolation of high-production CHO cell lines for use in manufacturing biologics
The data derived from studies using CrownBio’s portfolio showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy tes...
1 of 3
Receive JSR Life Sciences news on your RSS reader.
